Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP).
Sharma P, Kimler BF, O'Dea A, Nye L, Wang YY, Yoder R, Staley JM, Prochaska L, Wagner J, Amin AL, Larson K, Balanoff C, Elia M, Crane G, Madhusudhana S, Hoffmann M, Sheehan M, Rodriguez R, Finke K, Shah R, Satelli D, Shrestha A, Beck L, McKittrick R, Pluenneke R, Raja V, Beeki V, Corum L, Heldstab J, LaFaver S, Prager M, Phadnis M, Mudaranthakam DP, Jensen RA, Godwin AK, Salgado R, Mehta K, Khan Q.
Sharma P, et al.
Clin Cancer Res. 2021 Feb 15;27(4):975-982. doi: 10.1158/1078-0432.CCR-20-3646. Epub 2020 Nov 18.
Clin Cancer Res. 2021.
PMID: 33208340
Free PMC article.
Clinical Trial.
PATIENTS AND METHODS: Patients aged 18 years with stage I-III TNBC were randomized (1:1) to receive either paclitaxel (P) weekly 12 plus carboplatin AUC6 every 21 days 4 followed by doxorubicin/cyclophosphamide (AC) every 14 days 4 (CbP AC, arm A), or carboplatin AUC6 + docetaxel …
PATIENTS AND METHODS: Patients aged 18 years with stage I-III TNBC were randomized (1:1) to receive either paclitaxel (P) weekly 12 plus car …